HIGH-INTENSITY FOCUSED ULTRASOUND
HIFU: NO NEEDLES, NO INCISIONS

HIFU uses a concave piezoelectric transducer to focus multiple ultrasound beams (0.8-3.5 MHz) to a single point within the body — analogous to a magnifying glass focusing sunlight. At the focal point, acoustic energy is converted to heat through viscous absorption, reaching 65-100 degrees C in 1-3 seconds.

“The tissue between the skin and the focal point receives only a fraction of the energy — not enough to cause damage. Only at the focal point is there sufficient energy density for thermal ablation.”

• Acoustic Focusing: The Magnifying Glass Analogy

  The HIFU transducer focuses ultrasound waves from a large surface area to a focal point 1-3 mm in diameter. Acoustic intensity at the focal point is orders of magnitude higher than at the skin surface — enabling destructive temperatures at depth without damaging overlying tissue.

• Thermal Ablation at the Focal Point

  At 65-100 degrees C sustained for 1-3 seconds, irreversible coagulation necrosis occurs in a precisely defined focal zone. By systematically moving the focal point throughout the tumour volume in a series of ablation spots, the entire tumour can be destroyed from outside the body.

• Cavitation: The Second Mechanism

  At high acoustic intensities, cavitation — the formation and violent collapse of microscopic bubbles in tissue — contributes to mechanical tissue destruction. Inertial cavitation generates extreme local temperatures and pressures, adding to the thermal ablation effect and enhancing cell killing.

• Acoustic Windows: Why HIFU Cannot Reach Every Tumour

  HIFU requires an unobstructed acoustic window — a path of soft tissue without bone, gas, or air between the transducer and the target. Ribs block the acoustic path to some liver tumours. Bowel gas blocks pancreatic access. Skull attenuates ultrasound (transcranial MRgFUS uses specialised phased array transducers). Patient selection must carefully assess acoustic access.

HIFU has established clinical applications across both oncological and non-oncological indications. Its non-invasiveness makes it particularly valuable for patients who cannot undergo anaesthesia or needle-based procedures.

• Uterine Fibroids (Most Common HIFU Application Globally)

  MRI-guided HIFU (MRgFUS) for uterine fibroids is the largest single clinical application of HIFU worldwide. China subsidises MRgFUS for fibroids through national health insurance — the worlds most active programme. Achieves 50-80% fibroid volume reduction without surgery or hospital admission, preserving the uterus and fertility. The JC and HAIFU systems perform the majority of procedures globally.

• Prostate Cancer: Whole-Gland and Focal HIFU

  Transrectal HIFU (using an endoluminal transducer inserted rectally) for localised prostate cancer is an established guideline-recognised treatment option. Focal HIFU targets only the dominant cancer focus, reducing side effects while achieving local cancer control. Available at specialist centres in China and India for both primary treatment and salvage after radiation failure.

• Liver Cancer: HCC and Liver Metastases

  Extracorporeal HIFU for HCC is the most extensively studied oncological HIFU application — China has the worlds largest HCC HIFU dataset from the HAIFU programme. Used for HCC not amenable to ablation or surgery, subcostal lesions with adequate acoustic access, and in combination with TACE. Requires careful patient selection to ensure acoustic window access.

• Pancreatic Cancer: Pain Relief and Local Control

  HIFU for locally advanced pancreatic cancer is one of the most important emerging applications — pain palliation from nerve plexus destruction and local tumour control in combination with chemotherapy. China has the worlds largest clinical experience in pancreatic HIFU. Achieves significant pain reduction in 80-90% of patients with pancreatic cancer-related pain.

• Bone Metastases: Non-Invasive Pain Palliation

  MRI-guided HIFU for painful bone metastases achieves pain palliation without needle insertion — the first completely non-invasive image-guided ablation for bone. FDA-approved for palliative treatment of bone metastases. Particularly useful for patients with coagulation disorders or on anticoagulants where percutaneous needle procedures carry bleeding risk.

• 65-100 CTemperature at HIFU focal pointSufficient for irreversible coagulation necrosis in 1-3 seconds — delivered without any physical contact with the target tissue.
• 80-90%Pain relief rate with HIFU for pancreatic cancerOne of the most valuable applications in advanced pancreatic cancer — significant pain reduction without needle insertion.
• 50-80%Fibroid volume reduction with MRgFUS at 12 monthsNon-surgical uterine preservation — the most practiced HIFU application globally.
• <90 minAverage operating room time for one HIFU sessionUseful for showing treatment efficiency and same-day workflow in fibroid practice.
• 78.2%5-year failure-free survival with focal HIFU for prostate cancerLarge multicenter data showed durable medium-term cancer control with a low probability of needing whole-gland salvage treatment.
• 17.6%2-year reintervention rate after MR-HIFU for uterine fibroidsMost women avoided another procedure within two years, supporting HIFU as a meaningful uterus-preserving option in selected patients.

From acoustic window assessment to treatment at the most experienced HIFU programmes globally.

1. 1

   Case Review and Acoustic Window Assessment

   Review of imaging to determine whether an adequate acoustic window exists for HIFU access to the target — the critical first step in HIFU eligibility assessment. Tumour location, overlying structures, and body habitus all affect acoustic access.

2. 2

   Centre Matching

   Third Military Medical University Chongqing (HAIFU programme) for extracorporeal HIFU. Leading urology centres for prostate HIFU. Gynaecological HIFU centres with MRgFUS for uterine fibroids. Tata Memorial Centre and Apollo Hospitals for India-based access.

3. 3

   Remote HIFU Specialist Consultation

   Pre-travel consultation with the HIFU specialist team to confirm eligibility, review imaging for acoustic window suitability, and provide a preliminary treatment protocol before the patient commits to travel.

4. 4

   Travel and Procedure Logistics

   Many HIFU procedures are outpatient or 1-2 day admissions. Multiple sessions may be required for large tumours. CancerFax arranges medical visa, accommodation, and in-country interpretation support.

5. 5

   Post-Treatment Follow-Up

   MRI at 4-6 weeks assesses the non-perfused volume (NPV) — the HIFU ablation zone. CancerFax coordinates remote imaging review and supports the decision on need for additional sessions or complementary treatment.

Each page covers one HIFU topic in depth.

Frequently Asked Questions